Citations (27)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Walter Ageno, Jan Beyer-Westendorf & Andrea Rubboli. (2017) Once- versus twice-daily direct oral anticoagulants in non-valvular atrial fibrillation. Expert Opinion on Pharmacotherapy 18:13, pages 1325-1332.
Read now
Read now
Martin Feuring & Joanne van Ryn. (2016) The discovery of dabigatran etexilate for the treatment of venous thrombosis. Expert Opinion on Drug Discovery 11:7, pages 717-731.
Read now
Read now
Helen Mani & Edelgard Lindhoff-Last. (2014) New oral anticoagulants in patients with nonvalvular atrial fibrillation: a review of pharmacokinetics, safety, efficacy, quality of life, and cost effectiveness. Drug Design, Development and Therapy 8, pages 789-798.
Read now
Read now
Vivencio Barrios & Carlos Escobar. (2012) New evidences for old concerns with oral anticoagulation in atrial fibrillation: focus on dabigatran. Expert Opinion on Pharmacotherapy 13:18, pages 2649-2661.
Read now
Read now
Articles from other publishers (23)
Diona Gjermeni, Nertila Poci Saglam, Christoph B Olivier & Volker Kühlkamp. (2023) Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation. European Heart Journal Open 3:4.
Crossref
Crossref
Xiaole Su, Bingjuan Yan, Lihua Wang, Hong Cheng & Yipu Chen. (2022) Comparative efficacy and safety of oral anticoagulants for the treatment of venous thromboembolism in the patients with different renal functions: a systematic review, pairwise and network meta-analysis. BMJ Open 12:2, pages e048619.
Crossref
Crossref
Nemin Chen, Nico Gabriel, Maria M. Brooks & Inmaculada Hernandez. (2021) Joint Latent Class Analysis of Oral Anticoagulation Use and Risk of Stroke or Systemic Thromboembolism in Patients with Atrial Fibrillation. American Journal of Cardiovascular Drugs 21:5, pages 573-580.
Crossref
Crossref
Lianfang Ni, Xiahuan Chen, Meilin Liu, Yan Fan, Zhifang Fu, Dan Sun & Zhijie Zhao. (2020) Evaluation of Extended-Interval Dabigatran Dosing in Older Patients With Non-Valvular Atrial Fibrillation. Journal of Cardiovascular Pharmacology and Therapeutics 26:4, pages 359-364.
Crossref
Crossref
Giuseppe Patti & Sylvia Haas. (2021) Non–Vitamin K Antagonist Oral Anticoagulants and Factors Influencing the Ischemic and Bleeding Risk in Elderly Patients With Atrial Fibrillation: A Review of Current Evidence. Journal of Cardiovascular Pharmacology 77:1, pages 11-21.
Crossref
Crossref
Hiroki Ueyama, Hirotaka Miyashita, Hisato Takagi, Christina Cruz, Alfred Burger, Alexandros Briasoulis & Toshiki Kuno. (2020) Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. Journal of Thrombosis and Thrombolysis 51:1, pages 102-111.
Crossref
Crossref
Nicola Ferri. 2021. Direct Oral Anticoagulants. Direct Oral Anticoagulants
27
40
.
Eduardo Arellano‐Rodrigo, Victor Fernandez‐Gallego, Irene López‐Vilchez, Patricia Molina, Maribel Díaz‐Ricart, M. Urooj Zafar, Juan J. Badimon, Joanne Ryn & Ginés Escolar. (2019) Idarucizumab, but not procoagulant concentrates, fully restores dabigatran‐altered platelet and fibrin components of hemostasis. Transfusion 59:7, pages 2436-2445.
Crossref
Crossref
Anthony J. Comerota & Eduardo Ramacciotti. (2016) A Comprehensive Overview of Direct Oral Anticoagulants for the Management of Venous Thromboembolism. The American Journal of the Medical Sciences 352:1, pages 92-106.
Crossref
Crossref
Karl-Heinz Liesenfeld, Fredrik Gruenenfelder & Andreas Clemens. (2016) Enhanced elimination of dabigatran: Identifying the appropriate patient for the use of continuous venovenous hemodialysis instead of intermittent hemodialysis-A simulation analysis. The Journal of Clinical Pharmacology 56:5, pages 597-608.
Crossref
Crossref
Walid Amara & Sotiris Antoniou. (2016) Benefits of once-daily dosing with non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. European Heart Journal Supplements 18:suppl D, pages D1-D6.
Crossref
Crossref
Mahsa Keshtkaran, John Hearne, Babak Abbasi & Leonid Churilov. (2015) Stroke care systems: Can simulation modeling catch up with the recent advances in stroke treatment?. Stroke care systems: Can simulation modeling catch up with the recent advances in stroke treatment?.
Herm Brinkman. (2015) Global assays and the management of oral anticoagulation. Thrombosis Journal 13:1, pages 9.
Crossref
Crossref
Andreas Clemens, Herbert Noack, Martina Brueckmann & Gregory Y. H. Lip. (2014) Twice- or Once-Daily Dosing of Novel Oral Anticoagulants for Stroke Prevention: A Fixed-Effects Meta-Analysis with Predefined Heterogeneity Quality Criteria. PLoS ONE 9:6, pages e99276.
Crossref
Crossref
Carl-Erik Dempfle. (2014) Direct Oral Anticoagulants—Pharmacology, Drug Interactions, and Side Effects. Seminars in Hematology 51:2, pages 89-97.
Crossref
Crossref
Huijun Wei, Jin Shang, CarolAnn Keohane, Min Wang, Qiu Li, Weihua Ni, Kim O’Neill & Madhu Chintala. (2017) A novel approach to assess the spontaneous gastrointestinal bleeding risk of antithrombotic agents using Apc min/+ mice. Thrombosis and Haemostasis 111:06, pages 1121-1132.
Crossref
Crossref
Gregory Connolly & Alex C. Spyropoulos. (2013) Practical issues, limitations, and periprocedural management of the NOAC’s. Journal of Thrombosis and Thrombolysis 36:2, pages 212-222.
Crossref
Crossref
O. J. Rider & E. B. Rider. (2013) The changing face of oral anticoagulants. British Dental Journal 215:1, pages 17-20.
Crossref
Crossref
K. Huber, S. J. Connolly, A. Kher, F. Christory, G.‐A. Dan, R. Hatala, R. G. Kiss, B. Meier, B. Merkely, B. Pieske, T. Potpara, J. Stępińska, N. Vene Klun, D. Vinereanu & P. Widimský. (2013) Practical use of dabigatran etexilate for stroke prevention in atrial fibrillation. International Journal of Clinical Practice 67:6, pages 516-526.
Crossref
Crossref
Karl-Heinz Liesenfeld, Alexander Staab, Sebastian Härtter, Stephan Formella, Andreas Clemens & Thorsten Lehr. (2013) Pharmacometric Characterization of Dabigatran Hemodialysis. Clinical Pharmacokinetics 52:6, pages 453-462.
Crossref
Crossref
Francesco Scaglione. (2013) New Oral Anticoagulants: Comparative Pharmacology with Vitamin K Antagonists. Clinical Pharmacokinetics 52:2, pages 69-82.
Crossref
Crossref
C.-E. Dempfle. (2012) Pharmakologie der neuen oralen AntikoagulanzienPharmacology of the new oral anticoagulants. Herz 37:4, pages 362-369.
Crossref
Crossref
Kate M. O'Dell, Daniel Igawa & Jerline Hsin. (2012) New Oral Anticoagulants for Atrial Fibrillation: A Review of Clinical Trials. Clinical Therapeutics 34:4, pages 894-901.
Crossref
Crossref